Alzamend Neuro (ALZN) Enterprise Value (2021 - 2026)

Alzamend Neuro has disclosed Enterprise Value across 6 years of filings, most recently posting $3.1 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 343.42% year-over-year to $3.1 million; the TTM figure through Apr 2026 stood at $3.1 million (up 343.42% YoY), while the FY2026 annual figure was $3.1 million, up 343.42% from the prior year.
• Enterprise Value came in at $3.1 million for Q2 2026 at Alzamend Neuro, down from $5.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $126.1 million in Q1 2022 to a low of -$1.3 million in Q2 2025.
• Average Enterprise Value over 5 years is $32.6 million, with a median of $5.4 million recorded in 2024.
• Year-over-year, Enterprise Value tumbled 146.91% in 2025 and jumped 343.42% in 2026.
• Over 5 years, Enterprise Value stood at $102.5 million in 2022, then plunged by 88.04% to $12.3 million in 2023, then slumped by 88.17% to $1.5 million in 2024, then surged by 256.05% to $5.2 million in 2025, then slumped by 40.15% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $3.1 million in Q2 2026, $5.5 million in Q1 2026, and $5.2 million in Q4 2025.